This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Asia Bio Partnering Forum

Event begins in:

  • 00
  • 00
  • 00
  • 00
Marina Bay Sands Convention Center
April 24—25, 2024 | SingaporeApril 29—30, 2024 | Virtual

Jing Xu
Investment Principal at LYFE Capital


Jing Xu serves as Investment Principal at LYFE Capital, specializing in investments within pharmaceutical companies as well as pharma value chain across APAC region. With a robust background that spans over a decade in the healthcare sector, Jing has held diverse positions, including investor, as well as strategy and BD leader at LYFE, Amgen and WuXi. Her extensive experience across the entire drug development lifecycle has enabled her to lead and actively support investments in notable portfolios such as MediLink, Sciwind, ST Pharm, Chemlex etc. Jing earned her PhD in Pharmaceutical Sciences from Northeastern University and holds a bachelor’s degree in Biology from Nanjing University.

LYFE Capital is a global pioneering healthcare investment platform with $2+Bn USD asset under management. LYFE believes that “Healthcare has no boundaries”, and that every new investment made has the potential to advance healthcare and solve the unmet needs for patients. LYFE Capital leverages the expertise and global resources to invest in and create value for healthcare companies across the globe. The experienced team brings a comprehensive understanding of the healthcare industry, and help portfolio maximize their potential in the dynamic international market.

Agenda Sessions

  • Cross border investment: from local discovery to global innovation